ArticlePloS one2013
Recombinant IL-7/HGFβ hybrid cytokine enhances T cell recovery in mice following allogeneic bone marrow transplantation.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Administration of Recombinant TAPBPL Protein Ameliorates Collagen-Induced Arthritis in Mice.International journal of molecular sciences · 2023Article
- Recombinant CD300c-Ig fusion protein attenuates collagen-induced arthritis in mice.Rheumatology (Oxford, England) · 2022Article
- ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses.Cellular & molecular immunology · 2021Article
- Identification of TAPBPL as a novel negative regulator of T-cell function.EMBO molecular medicine · 2021Article
- Skint8, a Novel B7 Family-Related Molecule, Negatively Regulates T Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Concise Review: Boosting T-Cell Reconstitution Following Allogeneic Transplantation-Current Concepts and Future Perspectives.Stem cells translational medicine · 2019Review
- In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.Cellular immunology · 2019Article
- Targeted deletion of c-Met in thymic epithelial cells leads to an autoimmune phenotype.Immunology and cell biology · 2018Article
- A CD300c-Fc Fusion Protein Inhibits T Cell Immunity.Frontiers in immunology · 2018Article
- A human recombinant IL-7/HGFβ hybrid cytokine enhances antitumor immunity in mice.American journal of cancer research · 2017Article
- Transplantation of Donor-Origin Mouse Embryonic Stem Cell-Derived Thymic Epithelial Progenitors Prevents the Development of Chronic Graft-versus-Host Disease in Mice.Stem cells translational medicine · 2017Article
- Lymphoid and Myeloid Recovery in Rhesus Macaques Following Total Body X-Irradiation.Health physics · 2015Article
- Efficient in vitro generation of functional thymic epithelial progenitors from human embryonic stem cells.Scientific reports · 2015Article
- c-Met signalling is required for efficient postnatal thymic regeneration and repair.Immunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell immunodeficiency is a major complication of bone marrow (BM) transplantation (BMT). Therefore, approaches to enhance T cell reconstitution after BMT are required. We have purified a hybrid cytokine, consisting of IL-7 and the β-chain of hepatocyte growth factor (HGFβ) (IL-7/HGFβ), from a unique long-term BM culture system. We have cloned and expressed the IL-7/HGFβ gene in which the IL-7 and HGFβ genes are connected by a flexible linker to generate rIL-7/HGFβ protein. Here, we show that rIL-7/HGFβ treatment enhances thymopoiesis after allogeneic BMT. Although rIL-7 treatment also enhances the number of thymocytes, rIL-7/HGFβ hybrid cytokine was more effective than was rIL-7 and the mechanisms by which rIL-7 and rIL-7/HGFβ increase the numbers of thymocytes are different. rIL-7 enhances the survival of double negative (DN), CD4 and CD8 single positive (SP) thymocytes. In contrast, rIL-7/HGFβ enhances the proliferation of the DN, SP thymocytes, as well as the survival of CD4 and CD8 double positive (DP) thymocytes. rIL-7/HGFβ treatment also increases the numbers of early thymocyte progenitors (ETPs) and thymic epithelial cells (TECs). The enhanced thymic reconstitution in the rIL-7/HGFβ-treated allogeneic BMT recipients results in increased number and functional activities of peripheral T cells. Graft-versus-host-disease (GVHD) is not induced in the rIL-7/HGFβ-treated BMT mice. Therefore, rIL-7/HGFβ may offer a new tool for the prevention and/or treatment of T cell immunodeficiency following BMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.